問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Infectious Disease

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

盧柏樑Lu, Po-Liang
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

29Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧柏樑

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Thoracic Medicine

List

3Cases

2017-06-01 - 2019-12-31

Phase II

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia

  • Condition/Disease

    Pseudomonas Aeruginosa Pneumonia

  • Test Drug

    Aerucin（aerubumab，AR-105）

Participate Sites
11Sites

Terminated10Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

2019-05-01 - 2021-12-30

Phase III

A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

  • Condition/Disease

    Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

  • Test Drug

    Sulbactam-ETX2514 (ETX2514SUL)

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

2018-01-01 - 2020-05-01

Phase III

A phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Pimodivir combined with standard care treatment in adolescents, adults, and elderly hospitalized patients with influenza A

  • Condition/Disease

    Influenza A Infection

  • Test Drug

    Pimodivir

Participate Sites
5Sites

Terminated4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB